Annotation Detail
Information
- Associated Genes
- FCGR2B
- Associated Variants
-
FCGR2B p.Ile232Thr (p.I232T)
(
ENST00000236937.13,
ENST00000367961.8,
ENST00000358671.10 )
FCGR2B p.Ile232Thr (p.I232T) ( ENST00000236937.13, ENST00000358671.10, ENST00000367961.8 ) - Associated Disease
- breast cancer
- Source Database
- CIViC Evidence
- Description
- 1325 HER2-positive breast cancer patients treated with trastuzumab and chemotherapy from the N9831 clinical trial were analyzed. There was a difference in disease-free survival for FCGR2B I232T, with I/I patients deriving benefit from trastuzumab (p<0.001) compared to the T carriers who did not (p=0.81). The interaction between FCGR2B genotype and treatment was statistically significant (p=0.03).
- Variant Origin
- Common Germline
- Variant Origin
- Common Germline
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1086
- Gene URL
- https://civic.genome.wustl.edu/links/genes/1843
- Variant URL
- https://civic.genome.wustl.edu/links/variants/458
- Rating
- 4
- Evidence Type
- Prognostic
- Disease
- Breast Cancer
- Evidence Direction
- Supports
- Evidence Level
- B
- Clinical Significance
- Poor Outcome
- Pubmed
- 24989892
Drugs